Ultrahuman vs Oura: Smart Ring Patent Battle Takes Critical Turn in US

Initial Ruling: Oura’s Victory

In a significant development for the wearable technology industry, healthtech startup Ultrahuman has encountered a major legal setback in its patent infringement dispute with Finnish wearable technology firm Oura. The US International Trade Commission’s (ITC) Administrative Law Judge issued an initial ruling on April 26, finding in favor of Oura and determining that both Ultrahuman and Chinese manufacturer RingConn had infringed on Oura’s patented smart ring technology.

Case Background and Patent Claims

The legal battle began in August 2023 when Oura, established in 2013, filed a complaint alleging that its competitors had copied both the physical design and core technology of its sleep- and health-monitoring rings. The complaint specifically cited multiple US patents covering hardware design, sensor integration, and signal processing algorithms.

Key Findings and Evidence

The Administrative Law Judge’s initial determination revealed that Ultrahuman and RingConn had violated all asserted claims of Oura’s valid patents. Notably, the ruling highlighted concerns about Ultrahuman’s credibility during the proceedings, including allegations of submitting false evidence regarding a purported manufacturing facility in Texas. In contrast, Oura was recognized for presenting credible witness testimony.

Market Impact and Future Implications

The judge’s ruling addressed concerns about market monopolization, noting that the US wearables market remains highly competitive with major players like Apple, Samsung, and Fitbit offering various alternatives. For Ultrahuman, which secured $35 million in funding in late 2023, this ruling could significantly impact its US market strategy and expansion plans.

Next Steps and Potential Outcomes

The ruling will now proceed to the full six-member ITC Commission for review. If upheld, the Commission could issue exclusion orders preventing the import of Ultrahuman and RingConn smart rings into the US market. Additionally, cease-and-desist orders could restrict sales through major e-commerce platforms and direct-to-consumer websites.

For Ultrahuman, which has been rapidly expanding its presence in India and overseas markets, a final ruling against the company could force a significant strategic pivot. Options may include product redesigns, patent licensing negotiations, or a shift in market focus away from the US market.